SEC Form 4: Temperato John bought $28,462 worth of shares (125,000 units at $0.23), increasing direct ownership by 10% to 1,427,522 units

$NMTR
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $NMTR alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Temperato John

(Last) (First) (Middle)
C/O 9 METERS BIOPHARMA, INC.
8480 HONEYCUTT RD, STE 120

(Street)
RALEIGH NC 27615

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
9 METERS BIOPHARMA, INC. [ NMTR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/06/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 07/06/2022 P 125,000(1) A $0.2277 1,427,522 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $0.2270 to $0.2279, inclusive. The reporting person undertakes to provide to 9 Meters Biopharma, Inc., any security holder of 9 Meters Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
Remarks:
/s/ Bethany Sensenig, as power of attorney 07/08/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $NMTR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NMTR

DatePrice TargetRatingAnalyst
7/8/2021$5.00Outperform
BMO Capital Markets
More analyst ratings

$NMTR
Press Releases

Fastest customizable press release news feed in the world

See more
  • 9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

    RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.Mark Sirgo, Chairman of the Board of 9 Meters, stated, "On behalf of the Board of Directors, I want to thank John for his service and dedication to the Company." The Board of Directors has appointed Bethany Sensenig, Chief Financial Officer of 9 Meters, to serve as interim Chief Executive Officer in addition to her current responsibiliti

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

    RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "We are enthusiastic about the potential of vurolenatide and NM-136 to deliver value to patients. We are exploring options to fund further advancement of these assets, including financing and other strategic alternatives."Clinical Development and Business HighlightsPresentations on vurolenatide and SBS at ASPEN 2

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

    RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity. Based on the response, the Company currently plans to submit an IND to the FDA for this indication in the second half of 2023 based on the completion of the preclinical program. An approved IND is a prerequisite for conducting Phase 1 clinical studies of NM-136

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NMTR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NMTR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NMTR
SEC Filings

See more

$NMTR
Leadership Updates

Live Leadership Updates

See more
  • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

    Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

    $AGRX
    $GNTA
    $NMTR
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Package Goods/Cosmetics
  • 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

    Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer."We're very pleased to have Ms. Sensenig join the 9 Meters team as Chief Financial Officer with over twenty years of business and strategic financial leadership experience at both early-stage and large biotechnology companies," said John Temperato, President & Chief

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

    RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications."We are very excited to have such talented individuals, each with lengthy and accomplished pharmaceutical and biotech backgrounds, join the 9 Meters team during this critical time of growth for our company," said John Temperato, President & Chief Executive Officer of 9 Meters Biopharma. "Ms. Liu's

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NMTR
Financials

Live finance-specific insights

See more
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022

    Positive final results from the vurolenatide Phase 2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimenClinical plans and activities are underway including site and patient recruitment to facilitate Phase 3 study initiation upon protocol finalization with FDA this quarterRALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended Septembe

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

    Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announcedVurolenatide End-of-Phase 2 meeting with FDA on track for 3QCash balance as of June 30, 2022 of $29.5 million; additional $20 million from previously announced July debt financing extends cash runway into 4Q 2023RALEIGH, NC / ACCESSWIRE / August 15, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the second quarter ended June 30, 2022.John Temperato, President & Chief Exe

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

    On track to report Phase 2 data for vurolenatide for short bowel syndrome and Phase 3 interim analysis for celiac disease in JuneCash balance as of March 31, 2022, of $37.2 million is expected to fund ongoing clinical programs and business operations into Q2 2023RALEIGH, NC / ACCESSWIRE / May 16, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the first quarter ended March 31, 2022.John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, commented: "This is

    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

$NMTR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more